GlassScriptPhysician profile
Alan Clifford Parent
NPI 1225031628
$4,519.54
in general payments reported to CMS, 2019-2025
28 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $197 · 2021: $591 · 2022: $207 · 2023: $304 · 2024: $1,783 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971 · Travel and Lodging: $617 · Consulting Fee: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.99 |
| Travel and Lodging | $617.04 |
| Consulting Fee | $543.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,998.49 | 2019-2025 | Clareon, Argos, Centurion |
| Biotissue Holdings INC. | $406.43 | 2024-2025 | |
| New World Medical,INC. | $300.52 | 2022-2025 | Clearpath, Via360, Streamline |
| Regeneron Healthcare Solutions, INC. | $262.84 | 2020-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $235.36 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $186.52 | 2019-2023 | |
| Rxsight INC | $152.83 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Ivantis, INC | $142.85 | 2019 | |
| Kala Pharmaceuticals, INC. | $119.69 | 2020-2021 | |
| Abbvie INC. | $95.03 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $82.71 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $70.77 | 2019-2024 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.78 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $53.79 | 2022-2025 | Vyzulta, Miebo |
| Leadiant Biosciences, INC. | $49.18 | 2023 | Cystaran |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $45.04 | 2023-2025 | Cequa |
| Shire North American Group INC | $37.03 | 2019 | |
| Glaukos Corporation | $32.19 | 2022 | |
| Amgen INC. | $31.77 | 2025 | Tepezza |
| Dompe US, INC. | $21.63 | 2021 | |
| Recordati_rare_diseases_inc. | $20.64 | 2025 | Panhematin |
| Astellas Pharma US INC | $19.90 | 2023 | |
| Lensar, INC. | $19.79 | 2025 | Lensar Laser System |
| Horizon Therapeutics Plc | $19.69 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $16.70 | 2023 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $14.83 | 2019 | |
| Sight Sciences, INC. | $13.84 | 2024 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Parent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.